drugset
drugset / Trial / NCT04626128

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

NCT04626128 ↗

Phase 1/2 Completed 27 enrolled Clearside Biomedical, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)

Timeline

Start
2020-12-15
Primary completion
2022-10-13
Completion
2022-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject CLS-AX Small molecule 0.03 mg Other
Subject CLS-AX Small molecule 0.1 mg Other
Subject CLS-AX Small molecule 0.5 mg Other
Subject CLS-AX Small molecule 1 mg Other
Background Aflibercept Protein / enzyme biologic 2 mg Intravitreal

Indications

wet macular degeneration